WILEX AG: WILEX AG provides funding strategy for the development of the ADC technology and, acting corporate actions
WILEX AG / Key word (s): Financing
11.23.2015 11:10
Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP – a service of EQS Group . AG
The issuer is solely responsible for the content of this announcement
Ad hoc announcement according to § 15 WpHG
-. Not for distribution, publication or transmission in the US, Canada, Japan and Australia –
WILEX AG provides funding strategy for the development of the ADC technology and, acting corporate actions
– adopted financing strategy the Company liquidity until end of 2016 provides
– cash capital increase by approximately 10% from authorized capital under exclusion of subscription rights with dievini
– cash capital increase from authorized capital with subscription rights
Munich, 23 November 2015 – The Management Board of WILEX AG (ISIN DE000A11QVV0 / WL6 / FWB) today adopted with the approval of the Supervisory Board a financing strategy that will ensure Pharma GmbH initially until the end of 2016, the development and marketing of ADC technology at the subsidiary Heidelberg. The multi-stage financing package is comprised of various capital measures. The main shareholder dievini Hopp BioTech holding GmbH & amp; Co. KG, Walldorf, supports this strategy and is under the assumption that the subscription price does not exceed 1.84 euros per share, willing to participate to the extent that in any event, EUR 10 million will be achieved. The transaction should be completed in the first half of 2016.
In order to ensure the short-term financing was decided today by the Board and approval by the Supervisory conducting two prospectus free cash capital increases from authorized capital. The aim of the Company receiving gross proceeds of up to EUR 2.5 million. The Authorized Capital 2012 / I is currently after partial utilization, on 27 August 2012 and on 10 April 2015 still 4,460,205.00 Euro.
Increase in share capital by approximately 10% from authorized capital under exclusion subscription rights
The WILEX AG plans to increase the share capital of the Company by 9,305,608.00 Euro by approximately 10% to 10,236,168.00 euros by issuing 930,560 new no-par value bearer shares with a pro rata amount of the share capital of EUR 1.00 increase. The increase in share capital shall increase from authorized capital against cash contributions under exclusion of subscription rights. These new shares will be exclusively the main shareholder dievini Hopp BioTech holding GmbH & amp; Co. KG offered. The issue price per share amounted to 1.84 euros and corresponds to the subscription price of the second capital increase with subscription rights. The shares of this first capital increase carry dividend rights as from 1 December 2015 respectively.
capital increase from authorized capital with subscription rights
In addition, WILEX AG plans to increase the share capital of the Company by EUR 10,236,168 , 00 (share capital after the capital increase has been registered under exclusion of subscription rights in the commercial register) by up to EUR 443,124.00 to up to 10,679,292.00 euros by issuing up to 443,124 new no-par value bearer shares with a pro rata amount of the share capital of EUR 1.00 against cash contributions. The subscription price is 1.84 euros per share. The “New Shares” carry dividend rights as from 1 December 2015 respectively. The Company shall from this transaction accrue to a proceeds of up to 815,348.00 Euro.
The up to 443,124 New Shares are from Oddo Seydler Bank AG, Frankfurt, to the shareholders by way of indirect subscription rights in the ratio 21 1 offered for subscription. 21 existing shares entitle to subscribe for one new share. The subscription ratio has been determined on the basis of a share capital of EUR 9,305,608.00, because – as this capital increase was decided on 23 November 2015 – the implementation of the first capital increase was not entered in the Commercial Register and the shares of the first capital increase therefore no subscription rights have. The main shareholder dievini Hopp BioTech holding GmbH & amp; Co. KG is therefore in relation to the shares of the first capital increase not entitled to subscribe. To ensure an even subscription ratio, one shareholder has waived its subscription rights from four old shares.
In addition, given the opportunity to the shareholders, their statutory subscription rights, other New shares, not for the subscription rights during the subscription period were exercised to acquire at the subscription price (oversubscription). Binding offers for such an oversubscription must be submitted within the subscription period.
The subscription period for the new shares will start on 25 November 2015 and ends on December 8, 2015. An organized trade in subscription rights will not take place.
All new shares from cash capital increases two to be admitted to trading without a prospectus in the regulated market (Prime Standard) at the Frankfurt Stock Exchange. The admission of the new WILEX shares in the existing listing on the Frankfurt Stock Exchange is scheduled for 14 December 2015 and provides for the initial listing on 15 December 2015 respectively.
Further details of the capital increase to the expected on 24 November 2015 published in the Federal Gazette (www.bundesanzeiger.de) and on the website of WILEX AG (www.wilex.de) rights offering be taken.
Additional financing measures
The modalities for additional financing steps are currently being developed in the company. In particular, forthcoming capital measures are likely to be subject to the securities prospectus requirement. Corresponding preparations are now started. The individual steps and details of further financing measures are planned for the first half 2016 will be announced by the Company at a later date. WILEX AG intends to use the proceeds primarily for the development of proprietary ADC technology (Targeted Antibody Conjugates Amanitin). The main objective is to optimize a PSMA antibodies-drug conjugate as first own ATAC candidates and to advance in the direction of early clinical development. In addition to pre-clinical studies include the establishment of the manufacturing process for the PSMA antibodies, the active ingredient Amanitin and the antibody-drug conjugate (ATAC) for contract manufacturers under GMP standard.
Important
This ad hoc report represents neither an offer to sell or constitute an invitation to buy securities. In particular, this document constitutes neither an offer of securities for sale nor the solicitation of an offer to buy any securities in the United States of America is . The shares of WILEX AG (the “Shares”) may not be in the United States or to “US persons” (as defined in Regulation S of the US Securities Act of 1933, as amended (the “Securities Act”) defined) or be offered or sold for the account of US persons, unless they are registered or exempt from registration under the Securities Act. The Shares have not been and will not be registered under the Securities Act. There will be no public offering of shares in the United States of America
Information and Explaination of the Issuer to this News:.
About WILEX
The WILEX AG a biopharmaceutical company that has set the clinical development activities in Munich and now assumes as the parent holding tasks. The focus of research and development is on the operative business of the subsidiary Heidelberg Pharma GmbH, Ladenburg, which further developed especially the innovative platform technology for antibody-drug conjugates (ADC technology) and preclinical offers services in the fields of drug discovery and development. WILEX has diagnostic and therapeutic product candidates REDECTANE (R) and RENCAREX (R) that are available for licensing and further development in Phase III for external partners. WILEX AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. For more information, see http://www.wilex.com
Contact IR / PR support WILEX AG MC Services AG Sylvia Wimmer Katja Arnold (CIRO) Corporate Communications Executive Director & amp. Partner Tel .: +49 (0) 89-41 31 38-29 Tel .: + 49-89-210 228-40 E-mail: investors [at] wilex.com Mobile: +49 160 9360 3022 Grillparzerstr. 18, 81675 München Email: katja.arnold [at] mc-services.eu class = “news_detail_table” & gt;
This communication contains certain forward-looking statements that reflect the Company’s business and the itself, ‘believes’ by the use of forward-looking terminology such as ‘estimates’, ‘expect’, ‘would’, ‘will’, ‘should’, ‘future’, ‘potential’ or similar expressions or by general discussion of strategy , plans or intentions of the Company stand out. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ of operations, financial position, earnings, achievements, or industry results materially different from any future results, performance or achievements , which are expressed or implied by such forward-looking. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We assume no obligation to update such forward-looking statements to reflect future events or developments.
11.23.2015 DGAP’s Distribution Services include Regulatory Announcements, Financial / Corporate News and Press Releases. DGAP-Media archive at www.dgap-medientreff.de and www.dgap.de
Language: German
Company: WILEX AG
Grillparzerstr. 18
81675 München
Germany
Telephone: +49 (0) 89 41 31 38-0
Fax: +49 ( 0) 89 41 31 38-99
Email: info@wilex.com
Internet: www.wilex.com
ISIN: DE000A11QVV0
WKN: A11QVV
Stock Exchanges: Regulated Market in Frankfurt (Prime Standard); Freiverkehr in Berlin, Dusseldorf, Munich, Stuttgart
End of News DGAP News-Service
No comments:
Post a Comment